Evidence map›Paper›PMID 36679931›Full record

ArticleVaccines2022

The BCG Moreau Vaccine Upregulates In Vitro the Expression of TLR4, B7-1, Dectin-1 and EP2 on Human Monocytes.

Paulo R Z Antas, Andreon S M da Silva, Lawrence H P Albuquerque, Matheus R Almeida, Evelyn N G S Pereira, Luiz R R Castello-Branco, Carlos G G de Ponte

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Paulo R Z AntasLaboratório de Imunologia Clínica, Instituto Oswaldo Cruz, Fiocruz, and Instituto Nacional de Ciência e Tecnologia em Tuberculose (INCT-TB), Rio de Janeiro 21040-900, Brazil.ORCID 0000-0002-6168-9185
Andreon S M da SilvaLaboratório de Imunologia Clínica, Instituto Oswaldo Cruz, Fiocruz, and Instituto Nacional de Ciência e Tecnologia em Tuberculose (INCT-TB), Rio de Janeiro 21040-900, Brazil.ORCID 0000-0001-5915-0888
Lawrence H P AlbuquerqueLaboratório de Imunologia Clínica, Instituto Oswaldo Cruz, Fiocruz, and Instituto Nacional de Ciência e Tecnologia em Tuberculose (INCT-TB), Rio de Janeiro 21040-900, Brazil.
Matheus R AlmeidaLaboratório de Imunologia Clínica, Instituto Oswaldo Cruz, Fiocruz, and Instituto Nacional de Ciência e Tecnologia em Tuberculose (INCT-TB), Rio de Janeiro 21040-900, Brazil.ORCID 0000-0002-5664-3764
Evelyn N G S PereiraLaboratório de Investigação Cardiovascular, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-900, Brazil.ORCID 0000-0001-5511-7036
Luiz R R Castello-BrancoLaboratório de Imunologia Clínica, Instituto Oswaldo Cruz, Fiocruz, and Instituto Nacional de Ciência e Tecnologia em Tuberculose (INCT-TB), Rio de Janeiro 21040-900, Brazil.
Carlos G G de PonteLaboratório de Imunologia Clínica, Instituto Oswaldo Cruz, Fiocruz, and Instituto Nacional de Ciência e Tecnologia em Tuberculose (INCT-TB), Rio de Janeiro 21040-900, Brazil.
Fundação Oswaldo Cruz · BRLeiden University · NL

Funding

Coordenação de Aperfeicoamento de Pessoal de Nível Superior Finance Code 001Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro Nota-10National Council for Scientific and Technological Development INCT-TBNational Council for Scientific and Technological Development PQ-2Oswaldo Cruz Foundation NA
6 · The paper itself

Abstract

Background: Tuberculosis (TB) is currently the second greatest killer worldwide and is caused by a single infectious agent. Since Bacillus Calmette−Guérin (BCG) is the only vaccine currently in use against TB, studies addressing the protective role of BCG in the context of inducible surface biomarkers are urgently required for TB control. Methods: In this study, groups of HIV-negative adult healthy donors (HD; n = 22) and neonate samples (UCB; n = 48) were voluntarily enrolled. The BCG Moreau strain was used for the in vitro mononuclear cell infections. Subsequently, phenotyping tools were used for surface biomarker detection. Monocytes were assayed for TLR4, B7-1, Dectin-1, EP2, and TIM-3 expression levels. Results: At 48 h, the BCG Moreau induced the highest TLR4, B7-1, and Dectin-1 levels in the HD group only (p-value < 0.05). TIM-3 expression failed to be modulated after BCG infection. At 72 h, BCG Moreau equally induced the highest EP2 levels in the HD group (p-value < 0.005), and higher levels were also found in HD when compared with the UCB group (p-value < 0.05). Conclusions: This study uncovers critical roles for biomarkers after the instruction of host monocyte activation patterns. Understanding the regulation of human innate immune responses is critical for vaccine development and for treating infectious diseases.

Indexed as

BCG vaccinebiomarkerinnate immunitymonocytetuberculosis

Identifiers

PMID36679931
PMCPMC9861981
OpenAlexW4313473064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.